The client needed a presentation for a board meeting to identify an appropriate indication for their primary asset. Additionally, the client’s board was keen to understand the regulatory and clinical pathways to market. This critical information would help them decide if this venture could be funded.
Lumanity’s Clinical & Regulatory team provided the client with a succinct presentation that included vital strategic and intelligent data paired with a recommendation for which of the three proposed indications would provide for the most optimized path to market.
The valued outcome
The organization’s board accepted our proposed strategy and the recommended indication for use.
This resulted in the approval of additional funding for the pre-clinical and non-clinical testing of the asset and the furthering of their development activities.